What specific severe intestinal complication is caused by clindamycin?

The use of lincosamides, particularly clindamycin, is most commonly associated with the development of pseudomembranous colitis. This condition is a form of superinfection driven by the uncontrolled proliferation of Clostridium difficile—a component of normal microflora—when other competing microbes are suppressed by the antibiotic. The pathogen produces enterotoxins that damage the intestinal mucosa, leading to ulceration, fever, and severe diarrhea, sometimes bloody.

What is the main pharmacokinetic advantage of clindamycin over lincomycin?

Clindamycin has a higher bioavailability (approx. 90%), and unlike lincomycin, its gastrointestinal absorption is independent of food intake.

What is the target and mechanism of action of clindamycin at the cellular level?

The drug inhibits protein synthesis during translocation by reversibly binding to the 50S ribosomal subunit of the bacterium.

What drugs is clindamycin combined with to treat tropical malaria and toxoplasmosis?

For chloroquine-resistant tropical malaria, clindamycin is combined with quinine; for toxoplasmosis, it is combined with pyrimethamine.

What is the MLS_B resistance phenotype?

It is cross-resistance where bacterial production of methylase enzymes leads to simultaneous resistance to macrolides, lincosamides, and streptogramins.

Clindamycin: Mechanism of Action, Spectrum and Uses

Clindamycin

Clindamycinum

For medical students2 min readUpdated 2026-10-10

Clindamycin is a semisynthetic lincosamide antibiotic. The drug exhibits potent activity against anaerobic flora and Gram-positive microorganisms, surpassing natural lincomycin in oral bioavailability.

Pharmacological groupLincosamides (semisynthetic antibiotic)

Mechanism of actionInhibition of translation (binding to the 50S ribosomal subunit)

Primary spectrumAnaerobes (including Bacteroides fragilis) and Gram-positive cocci

Available formsCapsules (150 mg and 300 mg); oral solution; 15% injection solution; vaginal cream

Mechanism of Action and Pharmacokinetics

Similar to other lincosamides, clindamycin inhibits protein synthesis during the translocation step by blocking peptide bond formation. Its primary target is the 50S ribosomal subunit, creating similarities to macrolides. The drug primarily exerts a bacteriostatic effect, although high concentrations can achieve a bactericidal effect.

Compared to lincomycin, clindamycin has several pharmacokinetic advantages: its bioavailability reaches ~90%, and gastrointestinal absorption is not affected by food intake. The duration of action is approximately 6 hours. A characteristic feature of the entire drug class is its ability to accumulate in bone tissue and joints.

Pharmacological Effects and Spectrum of Activity

The antimicrobial spectrum of clindamycin covers:

Gram-positive cocci: Staphylococci (including penicillinase-producing strains), streptococci, and pneumococci.
Gram-positive bacilli: Diphtheria pathogen (Corynebacterium diphtheriae).
Anaerobes: Pathogens of gas gangrene and tetanus (Clostridium perfringens, Clostridium tetani), as well as severe infections caused by Bacteroides fragilis.
Protozoal infections: High activity against Pneumocystis jirovecii, Toxoplasma gondii, and malaria parasites (Plasmodium spp. at high doses).

Cross-resistance to the drug is associated with the MLS_B phenotype: constitutive production of methylase enzymes (modifying the ribosomal target) confers simultaneous resistance to macrolides, lincosamides, and type B streptogramins.

Main Indications

Clindamycin is a drug of choice or an important component of combination therapy for the following conditions:

Anaerobic and mixed infections: Severe pathologies caused by Bacteroides and other anaerobic associations.
Tropical malaria: Used in combination regimens with quinine for chloroquine-resistant forms of Plasmodium falciparum, acting on the erythrocytic stage.
Toxoplasmosis: Used as an alternative treatment regimen in combination with pyrimethamine (in case of sulfonamide intolerance).
Bone and joint infections: Due to its property of depositing in bone tissue.

Adverse Effects and Resistance Mechanisms

The major concern with clindamycin use is the risk of antibiotic-associated conditions resulting from the suppression of normal intestinal microflora. Mechanisms of bacterial resistance to the drug include:

Target modification: Methylation of the ribosomal binding site via methylase enzymes (the primary pathway in Gram-positive microorganisms).
Enzymatic inactivation: Production of esterases that hydrolyze the drug structure.
Transport impairment: Decreased membrane permeability and active efflux (efflux pumps).

Administration and Dosage

The drug is available in various dosage forms for differentiated use:

Capsules (150 mg and 300 mg).
Oral syrup (75 mg per 5 mL).
15% solution for injection in 2 mL and 4 mL ampoules.
Vaginal cream.

Dosing regimen: Orally, doses range from 150 mg to 600 mg. Intramuscularly, 300 mg is administered twice daily. For severe infections, intravenous drip infusion is indicated in a total daily dose of 1.2 to 4.8 g (divided into 2–4 administrations).

Mnemonic

Clin-da-mycin = Macrolide Target (50S subunit) and Methylase Modification.

Frequently asked questions

What specific severe intestinal complication is caused by clindamycin?: The use of lincosamides, particularly clindamycin, is most commonly associated with the development of pseudomembranous colitis. This condition is a form of superinfection driven by the uncontrolled proliferation of Clostridium difficile—a component of normal microflora—when other competing microbes are suppressed by the antibiotic. The pathogen produces enterotoxins that damage the intestinal mucosa, leading to ulceration, fever, and severe diarrhea, sometimes bloody.
What is the main pharmacokinetic advantage of clindamycin over lincomycin?: Clindamycin has a higher bioavailability (approx. 90%), and unlike lincomycin, its gastrointestinal absorption is independent of food intake.
What is the target and mechanism of action of clindamycin at the cellular level?: The drug inhibits protein synthesis during translocation by reversibly binding to the 50S ribosomal subunit of the bacterium.
What drugs is clindamycin combined with to treat tropical malaria and toxoplasmosis?: For chloroquine-resistant tropical malaria, clindamycin is combined with quinine; for toxoplasmosis, it is combined with pyrimethamine.
What is the MLS_B resistance phenotype?: It is cross-resistance where bacterial production of methylase enzymes leads to simultaneous resistance to macrolides, lincosamides, and streptogramins.

Go deeper

Comparative pharmacokinetics of lincomycin and clindamycin
Molecular basis of the MLS_B phenotype and the role of methylases
Spectrum of antibacterial activity against anaerobes (Bacteroides fragilis)
Combination therapy for chloroquine-resistant malaria
Accumulation of lincosamides in bone tissue during osteomyelitis
Alternative pharmacotherapy regimens for toxoplasmosis involving lincosamides